{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:04Z","timestamp":1791685324345,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T00:00:00Z","timestamp":1416528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40265-014-0333-2","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T16:10:21Z","timestamp":1416586221000},"page":"2211-2215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":213,"title":["Ripasudil: First Global Approval"],"prefix":"10.1007","volume":"74","author":[{"given":"Karly P.","family":"Garnock-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,21]]},"reference":[{"issue":"2","key":"333_CR1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1358\/dof.2013.038.02.1924778","volume":"38","author":"GD Novack","year":"2013","unstructured":"Novack GD. RHO kinase inhibitors for the treatment of glaucoma. Drugs Future. 2013;38(2):107\u201313.","journal-title":"Drugs Future."},{"issue":"1","key":"333_CR2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coph.2012.09.012","volume":"13","author":"C Bucolo","year":"2013","unstructured":"Bucolo C, Salomone S, Drago F, et al. Pharmacological management of ocular hypertension: current approaches and future prospective. Curr Opin Pharmacol. 2013;13(1):50\u20135.","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"333_CR3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/02713683.2013.874444","volume":"39","author":"T Isobe","year":"2014","unstructured":"Isobe T, Mizuno K, Kaneko Y, et al. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39(8):813\u201322.","journal-title":"Curr Eye Res"},{"key":"333_CR4","unstructured":"D. Western Therapeutics Institute. DWTI announces the acquisition of marketing approval in japan for a drug for treating glaucoma and ocular hypertension, K-115 [media release]. 26 Sept 2014. http:\/\/www.dwti.co.jp ."},{"key":"333_CR5","unstructured":"D. Western Therapeutics Institute Inc. Notice of NDA application in Japan for a glaucoma treatment drug \u201cK-115 (nonproprietary name: Ripasudil hydrochloride hydrate\u201d by Kowa Company Limited [media release]. 10 Oct 2013. http:\/\/www.dwti.co.jp ."},{"key":"333_CR6","unstructured":"D. Western Therapeutics Institute Inc. Notice of completion of late phase III clinical study of glaucoma treatment drug \u201cK-115\u201d in Japan [media release]. 10 Apr 2013. http:\/\/www.dwti.co.jp ."},{"key":"333_CR7","unstructured":"Kowa Company Ltd. K-115 Clinical pharmacology study [JAPIC identifier JapicCTI-142456]. 2014. http:\/\/clinicaltrials.jp . Accessed 22 Oct 2014."},{"key":"333_CR8","unstructured":"D. Western Therapeutics Institute. Anti-glaucoma K-115 (Glanatec\u00ae ophthalmic solution 0.4\u00a0%). 2014. http:\/\/dwti.co.jp\/english\/business-outline\/product-pipeline\/anti-glaucoma-k-115 . Accessed 23 Oct 2014."},{"key":"333_CR9","doi-asserted-by":"crossref","unstructured":"Mizuno K, Matsumoto J. United States Patent No. US 8,193,193 B2: agent for prevention or treatment of glaucoma. 2012. http:\/\/patft.uspto.gov\/ . Accessed 23 Oct 2014.","DOI":"10.30875\/c4bcd64c-en"},{"issue":"2","key":"333_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2131\/fts.1.39","volume":"1","author":"E Wato","year":"2014","unstructured":"Wato E, Omichi K, Yoneyama S, et al. Safety evaluation of morphological changes in corneal endothelial cells induced by K-115 in cynomolgus monkeys. Fundam Toxicol Sci. 2014;1(2):39\u201347.","journal-title":"Fundam Toxicol Sci."},{"issue":"10","key":"333_CR11","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","volume":"131","author":"HMD Tanihara","year":"2013","unstructured":"Tanihara HMD, Inoue TMD, Yamamoto TMD, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131(10):1288\u201395.","journal-title":"JAMA Ophthalmol."},{"key":"333_CR12","unstructured":"Nakao S, Arita R, Isobe T, et al. Therapeutic potential of topical ROCK inhibitor K-115 in retinal neovascularization [abstract no. FP-SA-51-4]. In: World Ophthalmology Congress. Tokyo; 2014."},{"key":"333_CR13","unstructured":"Yoshioka T, Nakabayashi S, Nagaoka T, et al. Effect of intravitreal Rho kinase inhibitors on retinal microcirculation in cats [abstract no. 6855-D1185]. In: Association for research in vision and ophthalmology annual meeting. Fort Lauderdale; 2012."},{"key":"333_CR14","doi-asserted-by":"crossref","unstructured":"Yamamoto K, Maruyama K, Himori N, et al. The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci. 2014. doi: 10.1167\/iovs.13-13842 .","DOI":"10.1167\/iovs.13-13842"},{"key":"333_CR15","unstructured":"Mizuno K, Koide T, Fujieda J, et al. Ocular hypotensive and neuroprotective effects on K-115, a novel Rho-kinase inhibitor [abstract no. 4805-B998]. Invest Ophthalmol Vis Sci. 2007;48."},{"key":"333_CR16","unstructured":"Japanese Pharmaceuticals and Medical Devices Agency. Glanatec\u00ae (ripasudil hydrochloride hydrate ophthalmic solution 0.4\u00a0%): Japanese prescribing information. 2014. http:\/\/www.info.pmda.go.jp\/ . Accessed 22 Oct 2014."},{"issue":"4","key":"333_CR17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731\u20136.","journal-title":"Am J Ophthalmol"},{"key":"333_CR18","unstructured":"Yamamoto T, Abe H, Kuwayama Y, et al. Efficacy and safety of the Rho kinase inhibitor, K-115, over 24\u00a0h in patients with primary open-angle glaucoma and ocular hypertension [abstract no. 216\/A512]. In: Association for research in vision and ophthalmology annual meeting. Orlando; 2011."},{"key":"333_CR19","unstructured":"Yamamoto T, Tanihara H, Kuwayama Y, et al. Phase 3 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension [abstract no. FP-TH-12-6]. In: World Ophthalmology Congress. Tokyo; 2014."},{"key":"333_CR20","unstructured":"Tanihara H, Yamamoto T, Kuwayama Y, et al. Phase 3 randomized clinical studies of a Rho kinase inhibitor, K-115, in combination with timolol or latanoprost in primary open-angle glaucoma and ocular hypertension [abstract no. FP-TH-12-7]. In: World Ophthalmology Congress. Tokyo; 2014."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0333-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0333-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0333-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T18:01:35Z","timestamp":1566064895000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0333-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,21]]},"references-count":20,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0333-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,21]]}}}